Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Hospitals can use a gentler dialysis plan now; a new RNA drug showed progress toward a hepatitis B cure; lab advances point to smaller, longer-lasting mRNA vaccines; and one test reads proteins and genes at once to guide care.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Personal shares from Christin here →
http://christin.substack.com/

Good news: A gentler, “as‑needed” dialysis schedule helped more ICU patients with sudden kidney failure come off dialysis sooner, with fewer treatments. That means less time on machines and faster recovery.

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis‑Requiring Acute Kidney Injury (LIBERATE‑D) Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (practice‑ready: uses existing dialysis equipment and criteria; U.S. hospitals could apply this protocol now without new approvals). 

Good news: In people with chronic hepatitis B, adding an investigational small‑interfering RNA (elebsiran) to pegylated interferon led to higher rates of functional cure (loss of HBsAg) than interferon alone in a phase 2 study.

Elebsiran and PEG‑IFNα for chronic hepatitis B infection: a partially randomized, open‑label, phase 2 trial

Market readiness: 🙂🙂🙂 (phase 2 human trial with encouraging efficacy; not FDA‑approved yet, larger confirmatory trials still needed). 

Good news: Scientists built new, degradable ionizable lipids that deliver mRNA more effectively in flu vaccine experiments, which could lead to lower doses and better tolerability.

Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines

Market readiness: 🙂🙂 (promising preclinical platform chemistry; human testing would be the next step). 

Good news: A chemical “boost” kept base‑modified mRNA stable for longer in lab models, potentially extending how long mRNA therapies work—so patients might need fewer doses.

RNA stability enhancers for durable base‑modified mRNA therapeutics

Market readiness: 🙂 (early laboratory work on a platform technology; clinical translation has not started). 

Good news: A new sequencing method reads proteins and RNA from the same tiny sample, giving a more complete picture of disease biology from a single biopsy—useful for picking the right treatment.

PLAMseq enables the proteo‑genomic characterization of complex samples

Market readiness: 🙂 (research‑lab method; clinical lab validation and regulatory steps would come later). 

Thank you for taking the time to take care of yourself and your loved ones.